Fibroblast Growth Factor 23, Endogenous Erythropoietin, Erythropoiesis-Stimulating Agents, and Erythropoietin Resistance in Hemodialysis Patients

被引:0
|
作者
Hamano, Naoto [1 ,2 ]
Komaba, Hirotaka [1 ,3 ]
Tanaka, Hisae [1 ]
Takahashi, Hiroo [4 ,5 ]
Takahashi, Yuichiro [5 ]
Hyodo, Toru [6 ]
Hida, Miho [6 ]
Suga, Takao [7 ]
Wada, Takehiko [8 ]
Kakuta, Takatoshi [1 ,9 ]
Fukagawa, Masafumi [1 ]
机构
[1] Tokai Univ, Sch Med, Div Nephrol Endocrinol & Metab, Isehara, Japan
[2] Shin Yurigaoka Gen Hosp, Dept Nephrol, Kawasaki, Japan
[3] Tokai Univ, Inst Med Sci, Isehara, Japan
[4] Tokai Univ, Oiso Hosp, Div Nephrol & Diabet, Oiso, Japan
[5] Jinken Clin, Ebina, Japan
[6] Med Corp Kuratakai, Hiratsuka, Japan
[7] Med Corp SHOWAKAI, Tokyo, Japan
[8] Toranomon Gen Hosp, Dept Nephrol, Tokyo, Japan
[9] Tokai Univ, Hachioji Hosp, Div Nephrol Endocrinol & Metab, Hachioji, Japan
关键词
Anemia; Erythropoiesis-stimulating agents; Erythropoietin; Fibroblast growth factor 23; ANEMIA; FGF23; INFLAMMATION; MORTALITY; PHOSPHATE; BONE;
D O I
10.1159/000543506
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction:Recent experimental studies have reportedthatfibroblast growth factor 23 (FGF23) inhibits erythropoi-esis by suppressing erythropoietin (EPO) production anddownregulating the EPO receptor. Conversely, either en-dogenous or exogenous EPO has been shown to stimulateFGF23 production. However, little is known about the rela-tionships between FGF23, erythropoiesis-stimulating agent(ESA) treatment, ESA resistance, and endogenous EPO inhemodialysis patients.Methods:We analyzed cross-sectionaldata from a cohort of 654 maintenance hemodialysis patients.We examined the associations of intact or C-terminal FGF23with ESA treatment, ESA resistance index (ERI), hemoglobin,C-reactive protein, and endogenous EPO levels using linearregression models. EPO was measured only in patients notreceiving ESAs.Results:A total of 458 patients (70%) weretreated with ESAs. The median EPO concentration in non-ESAusers was 7.8 (interquartile range, 5.3-14.4) mIU/mL. Themedian levels of intact and C-terminal FGF23 were 1,598(interquartile range, 548-4,586) pg/mL and 38.7 (interquartilerange, 14.0-127.6) pmol/L, respectively, in non-ESA users and1,955 (interquartile range, 573-5,264) pg/mL and 41.4(interquartile range, 13.9-116.8) pmol/L, respectively, in ESAusers. After adjustment for potential confounders, higher ESAdose was associated with higher FGF23 levels measured byboth intact and C-terminal assays. Higher C-terminal FGF23was also associated with higher ERI, lower hemoglobin, andhigher endogenous EPO, but no such associations wereobserved for intact FGF23 levels.Conclusions:Both intact andC-terminal FGF23 showed similar associations with ESA dose,but they showed different patterns of association with otherparameters related to anemia. Further research is needed toelucidate the mechanisms underlying these differentassociations.(c) 2025 S. Karger AG, Basel
引用
收藏
页数:9
相关论文
共 50 条
  • [11] Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
    Goodkin, David A.
    Zhao, Junhui
    Cases, Aleix
    Nangaku, Masaomi
    Karaboyas, Angelo
    AMERICAN JOURNAL OF NEPHROLOGY, 2022, 53 (05) : 333 - 342
  • [12] Use of erythropoiesis-stimulating agents in obese hemodialysis patients
    Park, Sun-Hee
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2018, 37 (03) : 308 - 309
  • [13] Expression and function of erythropoietin receptors in tumors - Implications for the use of erythropoiesis-stimulating agents in cancer patients
    Sinclair, Angus M.
    Todd, Marque D.
    Forsythe, Kevin
    Knox, Susan J.
    Elliott, Steve
    Begley, C. Glenn
    CANCER, 2007, 110 (03) : 477 - 488
  • [14] Predictors of Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
    Kalantar-Zadeh, Kamyar
    Lee, Grace H.
    Miller, Jessica E.
    Streja, Elani
    Jing, Jennie
    Robertson, John A.
    Kovesdy, Csaba P.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (05) : 823 - 834
  • [15] Resistance to Erythropoiesis-Stimulating Agents Is Associated with Arterial Microcalcification in Early Hemodialysis Patients
    Won, Hye Sung
    Choi, Su Jin
    Yun, Yu Seon
    Shin, Ok-Ran
    Ko, Yoon Ho
    Kim, Young Soo
    Yoon, Sun Ae
    Kim, Young Ok
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [16] Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients
    Maruyama, Noriaki
    Otsuki, Tomoyasu
    Yoshida, Yoshinori
    Nagura, Chinami
    Kitai, Maki
    Shibahara, Nami
    Tomita, Hyoe
    Maruyama, Takashi
    Abe, Masanori
    AMERICAN JOURNAL OF NEPHROLOGY, 2018, 47 (06) : 406 - 414
  • [17] Efficacy estimation of erythropoiesis-stimulating agents using erythropoietin-deficient anemic mice
    Suzuki, Norio
    Sasaki, Yusuke
    Kato, Koichiro
    Yamazaki, Shun
    Kurasawa, Mitsue
    Yorozu, Keigo
    Shimonaka, Yasushi
    Yamamoto, Masayuki
    HAEMATOLOGICA, 2016, 101 (09)
  • [18] Selenium Associates With Response to Erythropoiesis-Stimulating Agents in Hemodialysis Patients
    Yasukawa, Minoru
    Arai, Shigeyuki
    Nagura, Michito
    Kido, Ryo
    Asakawa, Shinichiro
    Hirohama, Daigoro
    Yamazaki, Osamu
    Tamura, Yoshifuru
    Fujimaki, Michitaka
    Kobayashi, Sawako
    Mimaki, Masakazu
    Kodama, Hiroko
    Uchida, Shunya
    Fujigaki, Yoshihide
    Shibata, Shigeru
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (07): : 1565 - 1574
  • [19] Parathyroidectomy Improves the Consumption of Erythropoiesis-Stimulating Agents in Hemodialysis Patients
    Lee, Yu-Ting
    Tu, Chi-Wen
    Kam, Kam-Hong
    Ma, Tsung-Liang
    Kuo, Chin-Ho
    Lee, Ming-Yang
    Hsiao, Chih-Yen
    Chan, Michael W. Y.
    Hung, Peir-Haur
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [20] Use of erythropoiesis-stimulating agents in obese hemodialysis patients Reply
    El-Kannishy, Ghada M.
    KIDNEY RESEARCH AND CLINICAL PRACTICE, 2018, 37 (03) : 310 - 311